Photodynamic therapy as an innovative treatment for malignant pleural mesothelioma.
Photodynamic therapy (PDT) of the pleura is an experimental treatment aimed at eradicating residual microscopic disease after macroscopic complete resection of malignant pleural mesothelioma (MPM) by means of intracavitary administration. A light-based treatment, PDT consists of 3 components: a nontoxic photosensitizing compound, oxygen, and visible light. The treatment is FDA-approved for several oncological targets, but remains experimental for MPM. PDT can be combined with lung-sparing pleurectomy and decortication and does not preclude other treatments such as adjuvant chemotherapy and/or radiation therapy. Additionally, PDT appears to bolster an immunologic effect by rendering the cancer cells that have been destroyed by the light-activated photosensitizer more presentable to the immune system. Local control and survival rates have been sufficiently rewarding to merit ongoing development of this combination of surgical technique and PDT.
Friedberg
Joseph S
JS
Department of Thoracic Surgery, University of Pennsylvania Medical Center-Presbyterian, Philadelphia, Pennsylvania 19104, USA. joseph.friedberg@uphs.upenn.edu
D017024:Chemotherapy, Adjuvant; D006801:Humans; D008654:Mesothelioma / Q000188:drug therapy* / Q000276:immunology / Q000601:surgery; D018579:Patient Selection; D010778:Photochemotherapy; D010997:Pleural Neoplasms / Q000188:drug therapy* / Q000276:immunology / Q000601:surgery; D011013:Pneumonectomy; D018714:Radiotherapy, Adjuvant; D013906:Thoracoscopy; D016896:Treatment Outcome